Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer

Endocrine-Related Cancer

Volumn 19, Issue 2, 2012, Pages 181-195

  West, Nathan R ^a,b   Murphy, Leigh C ^c   Watson, Peter H ^a,b,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TREFOIL FACTOR 1; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA SUBUNIT; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 84860899960     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0326     Document Type: Article

References (65)

1. Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, Hiller-Hitchcock T, Hole K, Murphy LC & Watson PH 1999 Psoriasin (S100A7) expression and invasive breast cancer. American Journal of Pathology 155 2057-2066. (doi:10.1016/S0002-9440(10)65524-1)
2. Balkwill F, Charles KA & Mantovani A 2005 Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 211-217. (doi:10.1016/j.ccr.2005.02.013)
3. Bayliss J, Hilger A, Vishnu P, Diehl K & El-Ashry D 2007 Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clinical Cancer Research 13 7029-7036. (doi:10.1158/1078-0432.CCR-07-0587)
4. Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S & Nakshatri H 2004 Tumour necrosis factor and PI3-kinase control oestrogen receptor α protein level and its transrepression function. British Journal of Cancer 90 853-859. (doi:10.1038/sj.bjc.6601541)
5. Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E & Myal Y 2009 Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Archiv 454 647-656. (doi:10.1007/s00428-009-0770-6)
6. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S & Lazennec G 2007 Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Research 9 R15. (doi:10.1186/bcr1648)
7. Clevenger CV 2004 Roles and regulation of stat family transcription factors in human breast cancer. American Journal of Pathology 165 1449-1460. (doi:10.1016/S0002-9440(10)63403-7)
8. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC &Watson PH 2004 Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clinical Cancer Research 10 8720-8727. (doi:10.1158/1078-0432.CCR-04-1235)
9. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM & El-Ashry D 2006 Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor a-negative human breast tumors. Cancer Research 66 3903-3911. (doi:10.1158/0008-5472.CAN-05-4363)
10. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L &Schiff R 2008 Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Research 68 7493-7501. (doi:10.1158/0008-5472. CAN-08-1404)
11. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR & Lee JC 1995 SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Letters 364 229-233. (doi:10.1016/0014-5793(95)00357-F)
12. D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P & Bonafe M 2010 Epigenetic control of the basal-like gene expression profile via interleukin-6 in breast cancer cells. Molecular Cancer 9 300. (doi:10.1186/1476-4598-9-300)
13. DeNardo DG & Coussens LM 2007 Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research 9 212. (doi:10.1186/bcr1746)
14. Deng G, Kakar S, Okudiara K, Choi E, Sleisenger MH & Kim YS 2009 Unique methylation pattern of oncostatin M receptor gene in cancers of colorectum and other digestive organs. Clinical Cancer Research 15 1519-1526. (doi:10.1158/1078-0432.CCR-08-1778)
15. Dhasarathy A, Kajita M & Wade PA 2007 The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-a. Molecular Endocrinology 21 2907-2918. (doi:10.1210/me.2007-0293)
16. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J et al. 2004 Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunology 5 752-760. (doi:10.1038/ni1084)
17. Dillon RL, White DE & Muller WJ 2007 The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26 1338-1345. (doi:10.1038/sj.onc.1210202)
18. Dudley DT, Pang L, Decker SJ, Bridges AJ & Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. PNAS 92 7686-7689. (doi:10.1073/pnas.92.17.7686)
19. EBCTCG 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 1687-1717. (doi:10.1016/S0140-6736(05)66544-0)
20. Fasnacht N & Muller W 2008 Conditional gp130 deficient mouse mutants. Seminars in Cell & Developmental Biology 19 379-384. (doi:10.1016/j.semcdb. 2008.07.001)
21. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F et al. 1998 Identification of a novel inhibitor of mitogen-activated protein kinase kinase. Journal of Biological Chemistry 273 18623-18632. (doi:10.1074/jbc.273.29.18623)
22. Garber K 2009 First results for agents targeting cancer-related inflammation. Journal of the National Cancer Institute 101 1110-1112. (doi:10.1093/jnci/djp266)
23. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R &Royuela M 2008 OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Investigation 26 222-229. (doi:10.1080/07357900701638491)
24. Grant SL & Begley CG 1999 The oncostatin M signalling pathway: reversing the neoplastic phenotype? Molecular Medicine Today 5 406-412. (doi:10.1016/S1357-4310(99)01540-3)
25. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK & Begley CG 2002 An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 21 460-474. (doi:10.1038/sj.onc.1205100)
26. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP &White BA 2012 Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Research and Treatment 132 75-85. (doi: 10.1007/s10549-011-1534-y)
27. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G & Schaper F 2003 Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal 374 1-20. (doi:10.1042/BJ20030407)
28. Holzer RG, Ryan RE, Tommack M, Schlekeway E &Jorcyk CL 2004 Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clinical &Experimental Metastasis 21 167-176. (doi:10.1023/B:CLIN.0000024760.02667.db)
29. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP & Taguchi H 2005 Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Molecular Cancer Therapeutics 4 578-586. (doi:10.1158/1535-7163.MCT-04-0277)
30. Jones SA, Scheller J & Rose-John S 2011 Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121 3375-3383. (doi:10.1172/JCI57158)
31. Jorcyk CL, Holzer RG & Ryan RE 2006 Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine 33 323-336. (doi:10.1016/j.cyto.2006.03.004)
32. Kan CE, Cipriano R & Jackson MW 2011 c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M. Cancer Research 71 6930-6939. (doi:10.1158/0008-5472.CAN-10-3860)
33. Kelly C, Jefferies C & Cryan SA 2011 Targeted liposomal drug delivery to monocytes and macrophages. Journal of Drug Delivery 2011 727241. (doi:10.1155/2011/727241)
34. Kim MS, Louwagie J, Carvalho B, Terhaar Sive Droste JS, Park HL, Chae YK, Yamashita K, Liu J, Ostrow KL, Ling S et al. 2009 Promoter DNA methylation of oncostatin M receptor-b as a novel diagnostic and therapeutic marker in colon cancer. PLoS ONE 4 e6555. (doi:10.1371/journal.pone.0006555)
35. Lopez-Tarruella S & Schiff R 2007 The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clinical Cancer Research 13 6921-6925. (doi:10.1158/1078-0432.CCR-07-1399)
36. Musgrove EA & Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nature Reviews. Cancer 9 631-643. (doi:10.1038/nrc2713)
37. Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B et al. 2007 Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen. Breast Journal 13 337-345. (doi:10.1111/j.1524-4741.2007.00440.x)
38. Naiditch H, Shurin MR & Shurin GV 2011 Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunologic Research 50 276-285. (doi:10.1007/s12026-011-8213-2)
39. Needham LA, Davidson AH, Bawden LJ, Belfield A, Bone EA, Brotherton DH, Bryant S, Charlton MH, Clark VL, Davies SJ et al. 2011 Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. Journal of Pharmacology and Experimental Therapeutics 339 132-142. (doi:10.1124/jpet.111. 183640)
40. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG &El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Molecular Endocrinology 15 1344-1359. (doi:10.1210/me.15.8.1344)
41. Osherov N & Levitzki A 1994 Epidermal-growth-factor-dependent activation of the src-family kinases. European Journal of Biochemistry 225 1047-1053. (doi:10.1111/j.1432-1033.1994.1047b.x)
42. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X & Perou CM 2010 Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 12 R68. (doi:10.1186/bcr2635)
43. Queen MM, Ryan RE, Holzer RG, Keller-Peck CR & Jorcyk CL 2005 Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Research 65 8896-8904. (doi:10. 1158/0008-5472.CAN-05-1734)
44. Reid G, Denger S, Kos M & Gannon F 2002 Human estrogen receptor-a: regulation by synthesis, modification and degradation. Cellular and Molecular Life Sciences 59 821-831. (doi:10.1007/s00018-002-8470-2)
45. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D et al. 2009 T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research 11 R15. (doi:10.1186/bcr2234)
46. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Colo GP, Nojek IM, Kordon EC, Nahmod VE & Costas MA 2006 TNF-a enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene 25 1367-1377. (doi:10.1038/sj.onc. 1209176)
47. Skliris GP, Hube F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E & Myal Y 2008 Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology 52 355-369. (doi:10.1111/j.1365-2559.2007.02955.x)
48. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
49. Sotiriou C & Pusztai L 2009 Gene-expression signatures in breast cancer. New England Journal of Medicine 360 790-800. (doi:10.1056/NEJMra0801289)
50. Speirs V, Kerin MJ, Walton DS, Newton CJ, Desai SB &Atkin SL 2000 Direct activation of oestrogen receptor-α by interleukin-6 in primary cultures of breast cancer epithelial cells. British Journal of Cancer 82 1312-1316. (doi:10.1054/bjoc.1999.1097)
51. Stearns V, Zhou Q & Davidson NE 2007 Epigenetic regulation as a new target for breast cancer therapy. Cancer Investigation 25 659-665. (doi:10.1080/07357900701719234)
52. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D, Chieco P et al. 2010 TNFα up-regulates SLUG via the NF-kappaB/HIF1α axis, which imparts breast cancer cells with a stem cell-like phenotype. Journal of Cellular Physiology 225 682-691. (doi:10.1002/jcp.22264)
53. Stossi F, Madak-Erdogan Z & Katzenellenbogen BS 2011 Macrophage-elicited loss of estrogen receptor-α in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus. Oncogene. (doi:10.1038/onc.2011.370)
54. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al. 2006 Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. Journal of Medicinal Chemistry 49 3563-3580. (doi:10.1021/jm060199b)
55. Tanaka M & Miyajima A 2003 Oncostatin M, a multifunctional cytokine. Reviews of Physiology, Biochemistry and Pharmacology 149 39-52. (doi:10.1007/s10254-003-0013-1)
56. Teschendorff AE, Journee M, Absil PA, Sepulchre R &Caldas C 2007a Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Computational Biology 3 e161. (doi:10.1371/journal.pcbi.0030161)
57. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO & Caldas C 2007b An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biology 8 R157. (doi:10.1186/gb-2007-8-8-r157)
58. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, Cameron PM, Meinke PT, Liverton N, Weng Y et al. 2002 Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorganic & Medicinal Chemistry Letters 12 1219-1223. (doi:10.1016/S0960- 894X(02)00106-3)
59. Underhill-Day N & Heath JK 2006 Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor b-specific kernel. Cancer Research 66 10891-10901. (doi:10.1158/0008-5472.CAN-06-1766)
60. Vlahos CJ, Matter WF, Hui KY & Brown RF 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Journal of Biological Chemistry 269 5241-5248.
61. Vogt A, Qian Y, McGuire TF, Hamilton AD & Sebti SM 1996 Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13 1991-1999. (Pubitemid 26397459)
62. Wang J, Barnes RO, West NR, Olson M, Chu JE & Watson PH 2008 Jab1 is a target of EGFR signaling in ERα-negative breast cancer. Breast Cancer Research 10 R51. (doi:10.1186/bcr2105)
63. West NR & Watson PH 2010 S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene 29 2083-2092. (doi:10.1038/onc.2009.488)
64. Whyte J, Bergin O, Bianchi A, McNally S & Martin F 2009 Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Research 11 209. (doi:10.1186/bcr2361)
65. Zhang F, Li C, Halfter H & Liu J 2003 Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22 894-905. (doi:10.1038/sj.onc.1206158)